Abstract
Severe acute respiratory disease coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although a primarily respiratory disease, recent reports indicate that it also affects the central nervous system (CNS). Over 25% of COVID-19 patients report neurological symptoms such as memory loss, anosmia, hyposmia, confusion, and headaches. The neurological outcomes may be a result of viral entry into the CNS and/or resulting neuroinflammation, both of which underlie an elevated risk for Alzheimer's disease (AD). Herein, we ask: Is COVID-19 a risk factor for AD? To answer, we identify the literature and review mechanisms by which COVID-19-mediated neuroinflammation can contribute to the development of AD, evaluate the effects of acute versus chronic phases of infection, and lastly, discuss potential therapeutics to address the rising rates of COVID-19 neurological sequelae.
Author supplied keywords
Cite
CITATION STYLE
Golzari-Sorkheh, M., Weaver, D. F., & Reed, M. A. (2023). COVID-19 as a Risk Factor for Alzheimer’s Disease. Journal of Alzheimer’s Disease. IOS Press BV. https://doi.org/10.3233/JAD-220800
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.